ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Monday, October 22, 2018

9:00AM-11:00AM
Abstract Number: 1299
A Novel Recombinant Oral Urate Oxidase (UrOx) Alln-346 Reduces Severe Hyperuricemia and Normalizes Hyperuricosuria in Nephropathic Urox Knockout (UrOxKO) Mice
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1365
A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1277
A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1243
A Quality Improvement Initiative to Increase Adherence to Hydroxychloroquine Dosing Guidelines at an Academic Medical Center
Measures and Measurement of Healthcare Quality Poster II
9:00AM-11:00AM
Abstract Number: 1429
A Quality Update: Improved Transfer Time Among Rheumatology Patients Transferring from Pediatric to Adult Care at an Academic Medical Center
Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
9:00AM-11:00AM
Abstract Number: 1730
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Systemic Sclerosis and Related Disorders – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1347
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science
9:00AM-11:00AM
Abstract Number: 1412
A Systematic Literature Review of Efficacy and Safety of Current Therapies for the Treatment of Hyperimmunoglobulinemia D Syndrome and TNF Receptor-Associated Periodic Syndrome
Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous
9:00AM-11:00AM
Abstract Number: 1105
Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis
Systemic Sclerosis and Related Disorders – Basic Science Poster II
9:00AM-11:00AM
Abstract Number: 1266
ABCG2 rs2231142 Q141K and Oxypurinol Concentration in People with Gout Receiving Allopurinol
Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 1766
Abdominal Adipose Tissue Predicts Incident Major Cardiovascular Events in Systemic Necrotizing Vasculitis Patients: Data from a Prospective Cohort Study on 120 Patients
Vasculitis – ANCA-Associated Poster I
9:00AM-11:00AM
Abstract Number: 1032
Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
Innate Immunity Poster
9:00AM-11:00AM
Abstract Number: 1333
Abnormal Function of High Density Lipoproteins in Idiopathic Inflammatory Myopathies
Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science
9:00AM-11:00AM
Abstract Number: 1465
Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis
9:00AM-11:00AM
Abstract Number: 1607
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies
  • «Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology